Fri. 22 Mar 2024, 7:15am ET
Benzinga
News, FDA
On 21 March 2024, The CHMP Adopted A Positive Opinion, Recommending The Granting Of A Marketing Authorization For Novartis' Fabhalta1, Intended For The Treatment Of Paroxysmal Nocturnal Haemoglobinuria
Company Profile